Published in Blood on April 01, 2002
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
How I treat EBV lymphoproliferation. Blood (2009) 2.18
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 1.39
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol (2004) 1.24
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16
Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. Immunol Cell Biol (2017) 1.09
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica (2010) 0.98
Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunology (2014) 0.91
Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol (2008) 0.91
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant (2011) 0.87
Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma. Pediatr Blood Cancer (2012) 0.86
Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood (2007) 0.86
Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol (2008) 0.86
Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol (2011) 0.85
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy (2010) 0.84
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy (2007) 0.84
Lymphoma Immunotherapy: Current Status. Front Immunol (2015) 0.84
Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol (2010) 0.83
Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol (2008) 0.82
Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity. Clin Dev Immunol (2013) 0.82
Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81
T cell therapy for nasopharyngeal carcinoma. J Cancer (2011) 0.81
Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol (2010) 0.81
T lymphocytes targeting native receptors. Immunol Rev (2014) 0.80
Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes. Immunology (2009) 0.80
Immunotherapy for epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis (2009) 0.79
Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J (2011) 0.79
Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol (2006) 0.79
Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med (2015) 0.78
Autologous human cytomegalovirus-specific cytotoxic T cells as rescue therapy for ulcerative enteritis in primary immunodeficiency. J Clin Immunol (2014) 0.76
Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. Update Cancer Ther (2008) 0.75
EBV-associated recurrent Hodgkin's disease after renal transplantation. Transpl Int (2006) 0.75
Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. Front Immunol (2017) 0.75
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75
Immunotherapy against cancer-related viruses. Cell Res (2016) 0.75
Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. Transplant Direct (2017) 0.75
EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation. Graefes Arch Clin Exp Ophthalmol (2003) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med (2014) 3.92
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut (2011) 3.81
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol (2004) 3.42
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev (2002) 2.86
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood (2009) 2.51
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol (2007) 2.38
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
Atypical features of familial hemophagocytic lymphohistiocytosis. Blood (2004) 2.21
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood (2009) 2.15
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
Percutaneous electrode guidance: a noninvasive technique for prelocation of peripheral nerves to facilitate peripheral plexus or nerve block. Reg Anesth Pain Med (2002) 2.10
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
Organ allocation waiting time during extracorporeal bridge to lung transplant affects outcomes. Chest (2013) 1.99
Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry (2012) 1.99
Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol (2008) 1.97
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol (2005) 1.83
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica (2008) 1.78
Mesenchymal stromal cells. Ann N Y Acad Sci (2009) 1.76
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 1.73
Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 1.72
Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol (2008) 1.71
Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case. Int J Hematol (2005) 1.71
Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin Transplant (2007) 1.70
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica (2010) 1.68
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Hepatic function after genetically engineered pig liver transplantation in baboons. Transplantation (2010) 1.64
Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol (2005) 1.64
Are human P[14] rotavirus strains the result of interspecies transmissions from sheep or other ungulates that belong to the mammalian order Artiodactyla? J Virol (2009) 1.62
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 1.58
Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant (2005) 1.58
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
Ethical reappraisal of 15 years of cord-blood transplantation. Lancet (2003) 1.55
A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood (2005) 1.54
Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy (2011) 1.54
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Surgical management of complex liver trauma: a single liver transplant center experience. Am Surg (2012) 1.53
Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2005) 1.51
Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica (2003) 1.51
Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol (2010) 1.51
Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood (2002) 1.49
Phylogenetic patterns of human respiratory picornavirus species, including the newly identified group C rhinoviruses, during a 1-year surveillance of a hospitalized patient population in Italy. J Clin Microbiol (2010) 1.49